Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex

IF 2.1 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Journal of Antibiotics Pub Date : 2025-01-07 DOI:10.1038/s41429-024-00803-6
Alicja Sękowska
{"title":"Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex","authors":"Alicja Sękowska","doi":"10.1038/s41429-024-00803-6","DOIUrl":null,"url":null,"abstract":"Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor. The aim of this study was to assess the susceptibility of multidrug-resistant KPc strains to AZA. The study included 52 ESβL-positive strains and 152 carbapenemase-positive KPc strains. The susceptibility to AZA was tested using the gradient strip method. AZA showed high activity against KPc, with MICs ranging from 0.032 to 0.75 μg ml-1 for ESβL-positive strains and from 0.016 to 2 μg ml-1 for carbapenemase-positive strains. The lowest MIC50 of AZA was obtained for VIM- and ESβL-positive strains at 0.094 μg ml-1, and MIC90 for ESβL-positive strains was 0.125 μg ml-1. AZA demonstrated excellent in vitro activity against the analysed strains, suggesting that this antibiotic may be an effective therapeutic option for treating infections caused by multidrug-resistant KPc strains.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"78 3","pages":"197-202"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antibiotics","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41429-024-00803-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor. The aim of this study was to assess the susceptibility of multidrug-resistant KPc strains to AZA. The study included 52 ESβL-positive strains and 152 carbapenemase-positive KPc strains. The susceptibility to AZA was tested using the gradient strip method. AZA showed high activity against KPc, with MICs ranging from 0.032 to 0.75 μg ml-1 for ESβL-positive strains and from 0.016 to 2 μg ml-1 for carbapenemase-positive strains. The lowest MIC50 of AZA was obtained for VIM- and ESβL-positive strains at 0.094 μg ml-1, and MIC90 for ESβL-positive strains was 0.125 μg ml-1. AZA demonstrated excellent in vitro activity against the analysed strains, suggesting that this antibiotic may be an effective therapeutic option for treating infections caused by multidrug-resistant KPc strains.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Aztreonam-avibactam:一种具有抗多药耐药肺炎克雷伯菌复合物活性的新组合。
肺炎克雷伯菌复合体(KPc)是一组对公共卫生构成严重威胁的机会性病原体。多药耐药性正在增加,并限制了治疗选择。Aztreonam-avibactam (AZA)是一种已建立的β-内酰胺与一种新的β-内酰胺酶抑制剂的组合。本研究的目的是评估多重耐药KPc菌株对AZA的敏感性。研究纳入52株es β l阳性菌株和152株碳青霉烯酶阳性KPc菌株。采用梯度条法检测菌株对AZA的敏感性。AZA对KPc具有较高的抑制活性,es β l阳性菌株的mic值为0.032 ~ 0.75 μg ml-1,碳青霉烯酶阳性菌株的mic值为0.016 ~ 2 μg ml-1。VIM-和es β l阳性菌株的MIC50最低为0.094 μg ml-1, es β l阳性菌株的MIC90最低为0.125 μg ml-1。AZA对所分析的菌株表现出良好的体外活性,表明该抗生素可能是治疗多重耐药KPc菌株引起的感染的有效治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Antibiotics
Journal of Antibiotics 医学-免疫学
CiteScore
6.60
自引率
3.00%
发文量
87
审稿时长
1 months
期刊介绍: The Journal of Antibiotics seeks to promote research on antibiotics and related types of biologically active substances and publishes Articles, Review Articles, Brief Communication, Correspondence and other specially commissioned reports. The Journal of Antibiotics accepts papers on biochemical, chemical, microbiological and pharmacological studies. However, studies regarding human therapy do not fall under the journal’s scope. Contributions regarding recently discovered antibiotics and biologically active microbial products are particularly encouraged. Topics of particular interest within the journal''s scope include, but are not limited to, those listed below: Discovery of new antibiotics and related types of biologically active substances Production, isolation, characterization, structural elucidation, chemical synthesis and derivatization, biological activities, mechanisms of action, and structure-activity relationships of antibiotics and related types of biologically active substances Biosynthesis, bioconversion, taxonomy and genetic studies on producing microorganisms, as well as improvement of production of antibiotics and related types of biologically active substances Novel physical, chemical, biochemical, microbiological or pharmacological methods for detection, assay, determination, structural elucidation and evaluation of antibiotics and related types of biologically active substances Newly found properties, mechanisms of action and resistance-development of antibiotics and related types of biologically active substances.
期刊最新文献
Correction: New potentiators of amphotericin B activity, shodoamides A to C produced by Pseudophialophora sp. BF-0158. Epiconone, one novel cyclohexenone from endophytic fungi Epicoccum sp. 1-042. The thiodiketopiperazine derivatives shovelmycin A-B and ansamycin derivative divergolide X from the cold-seep-derived Streptomyces olivaceus HDN22-001. The secondary metabolites of the alga-derived fungus Aspergillus niveoglaucus КММ 4176 and their antimicrobial and antibiofilm activities. Blue benzoquinone from scorpion venom shows bactericidal activity against drug-resistant strains of the priority pathogen Acinetobacter baumannii.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1